Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.

Arkadiusz Z. Dudek,Li C. Liu,Ajjai Alva,Mark N. Stein,Shilpa Gupta,Costantine Albany,Monika Joshi,Yousef Zakharia,Joshua Michael Lang,James K. Schwarz,Anas Al-Janadi

Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.

2018

Arkadiusz Z. Dudek
Li C. Liu
Ajjai Alva
Mark N. Stein
Shilpa Gupta
Costantine Albany
Monika Joshi
Yousef Zakharia
Joshua Michael Lang
James K. Schwarz
Anas Al-Janadi

4558Background: Hypoxic regions of RCC, impede homing of cytotoxic T cells into tumor. In addition, tumor angiogenesis enhances immunosuppressive activity of MDSC and TAM. Antiangiogenic therapy de...

Keywords:

Bevacizumab
Cancer research
Pathology
Renal cell carcinoma
Pembrolizumab
Medicine
tumor angiogenesis
antiangiogenic therapy
Cytotoxic T cell
Homing (biology)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations